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Abstract
Objective: Replication of HIV-1 after cell entry is es-
sentially dependent on the reverse transcriptase (Rt).
antiretroviral drugs impairing the function of the Rt
currently aim at the polymerase subunit. one reason
for  failure  of  antiretroviral  treatment  is  the  evolve-
ment  of  resistance-associated  mutations  in  the  viral
genome. for Rt inhibitors, almost all identified muta-
tions  are  located  within  the  polymerase;  therefore,
general  genotyping  confines  to  investigate  this  sub-
unit. Recently several studies have shown that substi-
tutions within the Rnase H and the connection do-
main  increase  antiviral  drug-resistance  in  vitro,  and
some of them are present in patient isolates.
Aim: the aim of the present study was to investigate
the prevalence of these substitutions and their associa-
tion with mutations in the polymerase domain arising
during antiretroviral treatment.
Material and Methods: we performed genotypic ana-
lyzes on seventy-four virus isolates derived from treat-
ed and untreated patients, followed at the HIV Centre
of the Johann wolfgang goethe university Hospital
(frankfurt/Main,  germany).  we  subsequently  ana  -
lysed the different substitutions in the c-terminal re-
gion to evaluate whether there were associations with
each other, n-terminal substitutions or with antiretro-
viral treatment.
Results:  we  identified  several  primer  grip  substitu-
tions, but almost all of them were located in the con-
nection domain. this is consistent with other in-vivo
studies, in which especially the primer grip residues lo-
cated in the Rnase H were unvaried. furthermore, we
identified  other  substitutions  in  the  connection  do-
main and in the Rnase H. Especially E399d seemed
to be associated with an antiretroviral treatment and
n-terminal resistance-delivering mutations. 
Conclusion: some of the identified substitutions were
associated with antiviral treatment and drug resistance-
associated mutations. due to the low prevalence of C-
terminal mutations and as only a few of them could be
associated with antiviral treatment and n-terminal re-
sistance-delivering  mutations,  we  would  not  recom-
mend routinely testing of the C-terminal Rt region. 
Key words: antiretroviral therapy, genotypic resistance,
reverse transcriptase, polymerase, Rnase H, connec-
tion domain
IntRoduCtIon
the development of antiretroviral therapy has reduced
the mortality and morbidity of HIV. several drugs are
available for the treatment of HIV, many of which are
inhibitors of the reverse transcriptase (Rt) [1].
Currently, two different classes of Rt-Inhibitors are
available,  non-nucleoside  reverse  transcriptase  in-
hibitors  (nnRtIs)  and  nucleoside  reverse  transcrip-
tase inhibitors (nRtIs).
the Rt has a high error rate; combined with the
high replication capacity of HIV (1-6 hours), muta-
tions resulting in antiviral drug-resistance can evolve
easily. since nRtIs block the polymerase subunit of
the  Rt,  nRtI-resistance  delivering  mutations  are
mainly expected to be located there. the commercially
available  genotyping  systems  confine  to  investigate
this subunit. 
nRtI-resistance  can  either  be  caused  by  an  en-
hanced excision or selectivity of the Rt [1-4]. Recently
it has been suggested that C-terminal mutations might
increase the timeframe for nRtI-excision by decreas-
ing the Rnase H activity [3, 5]. genotypic and pheno-
typic analyses of nRtI-experienced Rts showed that
mutations  in  the  connection  domain  (E312Q,
g335C/d, n348I, a360I/V, V365I and a376s) were
able to increase nRtI- resistance [6]. nikolenko et al.
proposed that such mutations might affect the Rnase
H primer grip, resulting in inefficient and unspecific
template-cleavage [7].
If C-terminal mutations prolong the timeframe for
nucleotide  excision,  additional  mutations  enhancing
nRtI-excision might lead to a synergistic increase in
antiretroviral  drug-resistance.  accordingly  almost  all
mutations described in previous studies could not en-
hance  azidothymidine  (aZt)-resistance  significantly,
unless they were combined with tymidinanalogue-re-
sistance  associated  mutations  (taMs)  [7,  8].  In  the
meantime several in vivo studies highlighting the need
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1) Stürmer_Umbruchvorlage  15.10.10  18:55  Seite 415for further investigation of the C-terminal region have
been published [9-12].
the aim of the present study was to investigate the
prevalence of C-terminal substitutions and to analyse
if  there  are  any  associations  with  n-terminal  resis-
tance-delivering mutations or antiretroviral treatment.
MatERIal and MEtHods
PatIEnts
seventy-four viral sequences from HIV-1 infected pa-
tients followed at the HIV Centre of the Johann wolf-
gang  goethe  university  Hospital  (frankfurt/Main,
germany) from october 2005 to august 2007 were
included in this study. the sequences were randomly
chosen, but only viral isolates with a subtype B ac-
cording to the pol gene region were integrated in this
study. furthermore, sequences of patients who were
in  a  treatment  interruption  (tI)  longer  than  six
months at the time of sample taking were excluded. 
the median viral load was 4900 copies/ml (range
306-10.000.000 copies/ml). 
gEnotyPIC REsIstanCE tEstIng
we  extracted  HIV-1  Rna  from  one  ml  of  Edta-
plasma using the QIaampﾮ Viral Rna Mini Kit (Qia-
gen, Hilden) according to the procedure recommend-
ed by the manufacturer.
the n-terminal region was amplified as previously
described  encompassing  the  polymerase  region  be-
tween codons 1 and 340 [13-15]. a semi-nested Rt
PCR was performed for the amplification of the C-
terminal region analyzing codons 340–560. the QIa-
gEnﾮ onestep Rt-PCR Kit (Qiagen, Hilden) was
applied for the outer PCR, while the inner PCR was
performed using the taq dna Polymerase and Q-so-
lution  Kit  (Qiagen,  Hilden).  the  following  primers
were used for Rt-PCR (position according to HXB2):
outer  PCR  forward:  5’-ggaCatatCaaatttat
CaagaRCCat-3’ (tib Molbiol, Berlin); outer PCR
Reverse:  5’-CaCtRgCyaCatgaaCtgCtaCCa-3’
(tib  Molbiol,  Berlin);  Inner  PCR  forward:  5’-gga
CatatCaaatttatCaagaRCCat-3’(tibMolbiol,
Berlin);  Inner  PCR  Reverse:  5’-tagCtgCCatattC
CKggRCtaC-3’ (tib Molbiol, Berlin).
the PCR product was sequenced using an in-house
sequencing assay and the primers mentioned above. for
purification of the sequencing product, the dyeEx 2.0
spin Kit was applied. genotyping was performed with
a  3100  avant  genetic  analyzer  (aBI  Prism,  darm-
stadt). the sequences were analyzed using the seqMan
Pro software (dnastaR, Inc., Konstanz).
Mutations  were  reported  as  amino  acid  changes
with  respect  to  the  sequence  of  the  wild-type  virus
HXB2. Mixtures were considered as mutated.
statIstICal MEtHods
all statistic calculations were done with the sPss soft-
ware (Version 16.0). Exact fisher’s test was used to
compare the prevalence of substitutions in the C-ter-
minal region of treatment-na￯ve patients and pre-treat-
ed patients. we also used fisher’s test to find associa-
tions between these substitutions and the frequency of
taMs,  nucleoside  analogue  mutations  (naMs)  and
nnRtI-resistance-associated  mutations.  for  all  tests




25 samples were derived from therapy-na￯ve and 49
samples  from  pre-treated  patients.  of  these,  43/49
were  derived  from  patients  with  aZt-medication  in
their  antiretroviral  history.  twenty-seven  sequences
were derived from patients taking nRtIs at the time
of the sample collection, 15 received aZt, 18 received
3tC and three received ftC (see table 1). the medi-
an number of nRtIs received by patients treated at
the time of sample drawing was two (range 0-5), while
the median number of protease inhibitors (PIs) was
zero  (range  0-3).  thirteen  samples  and  derived  se-
quences were collected from patients in treatment in-
terruption  (tI)  with  a  median  duration  of  four
months (range 1-6 months). 
n-tERMInal REsIstanCE-assoCIatEd MutatIons
twenty-seven of the seventy-four analyzed sequences
contained  resistance-associated  mutations  (see  table
1).  twenty-four  contained  taMs  (M41l,  d67n,
K70R,  l210w,  t215yf  and  K219QE).  the  median
number of taMs was three (range 1-4). sixteen con-
tained  additional  nRtI-resistance  associated  muta-
tions (naMs), e.g. K70E, l74VI, V75t, y115f and
the M184V mutation, which was present in all 16 se-
quences.  Eleven  sequences  contained  nnRtI-resis-
tance  associated  mutations  (K103n,  V179f,  y181C,
y188l and g190a).
aMIno aCId HEtERogEnEIty In tHE C-tERMInal
REgIon
seventy-four positions in the C-terminal part of the
HIV-1  Rt  that  have  previously  been  implicated  in
nRtI resistance were analyzed in this study. However,
we  could  not  evaluate  some  sequences  completely,
which is why there is insufficient data for some posi-
tions. the following positions were conserved among
the  treatment-na￯ve  and  pre-treated  patients:  y318,
H361, w401, f416, Q428, f440, a446, R448, d471,
t473, n474, Q475, t477, Q500, y501, I505, H539,
V548 and d549. only position 318, 361, 401 and 416
are part of the connection region; the other positions
are located in the Rnase H [8]. 55/74 examined posi-
tions (74%) showed amino acid heterogeneity. these
positions  were  mutated  among  the  pre-treated,  the
treatment-na￯ve patients or both (see table 2). 
assoCIatIon of MutatEd aMIno aCIds In tHE C-
tERMInal REgIon wItH antIREtRoVIRal
tREatMEnt
substitutions  at  three  positions  (369,  399  and  554)
were  associated  with  an  aZt-treatment  six  months
prior to sample taking. some substitutions (395, 520
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aZt-treatment six month prior to sample taking. the
only substitutions associated with a current antiretro-
viral therapy and a current nRtI-treatment were lo-
cated at position 399 (see table 3). additionally muta-
tions at position 524 and 554 were associated with a
current aZt-treatment. substitutions at position 554
also showed the tendency to be associated with a cur-
rent nRtI-treatment and an aZt-treatment any time
prior to sample taking. substitutions at position 520
showed the tendency to be associated with a current
antiretroviral treatment.
assoCIatIon of MutatEd aMIno aCIds In tHE
C-tERMInal REgIon wItH REsIstanCE-dElIVERIng
n-tERMInal MutatIons
several  C-terminal  substitutions  showed  associations
to  n-terminal  resistance-associated  mutations  (see
table 4).  
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Table 1. Baseline characteristics of the 49 pretreated viral isolates.
Characteristic Value
age, median years (IQR) 44 (23-80)
Plasma HIV-1 Rna level, median copies/ml (IQR) 4900  (range 306-10.000.000)
Previous antiretroviral therapy, median months (IQR) 124 (range 1-193)
treatment interruption (tI) at time of sample-taking
yes 13 (26,5)
no 36 (73,5)
duration of tI, median months (IQR) 4 (1-6)
nRtI used in antiretroviral treatment at time of sample taking
yes 27 (55,1)
no 22 (44,9)
Prior mono nucleoside treatment 
yes 20 (40,8)
no 29 (59,2)
Prior dual nucleoside treatment
yes 28 (57,1)
no 21 (42,9)
3tC used in antiretroviral treatment at time of sample-taking
yes 18 (36,7)
no 31 (63,3)
ftC used in antiretroviral treatment at time of sample-taking
yes 3 (6,1)
no 46 (93,9)












sequences containing taMs 24 (49)




sequences containing nnRtI resistance delivering mutations 11 (22,4)
nnRIt resistance delivering mutations, median no. (IQR) 1 (1-3)
notE. data are no. (%) of patients, unless otherwise specified. IQR, interquartile range, 3tC, 2',3'-dideoxy-3'-thiacytidine.
ftC, 2',3'-didesoxy-5-fluor-3'-thiacytidin.
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Table 2. Positions and frequencies of selected C-terminal mutations in sequences of viral isolate from HIV-1 infected patients.
amino acids in bold are only present in sequences derived from pre-treated patients (*).
therapy-na￯ve patients pre-treated patients
HXB2- substitutions in  substitutions total (%) substitutions total (%)
sequence total (%)
369 t 5 (8%) P 1 (4%) aIV 4 (10%)
395 K 9 (13%) R 2 (8%) R 7 (15%)
399 E 15 (21%) d 2 (8%) dgK 13 (29%)
520 Q 4 (5%) none 0 EHK 4 (8%)
524 Q 10 (14%) E 2 (8%) EK 8 (16%)
554 a 37 (51%) nst 10 (40%) nst 26 (54%)
* only the Positions and frequencies of C-terminal mutations that are either statistical associated or showing the tendency to be
associated with antiretroviral treatment are shown
Table 3. association of selected C-terminal mutations with antiretroviral treatment (*).
Position Current Current nRtI- Current aZt- Prior aZt- aZt-
according to  antiretroviral  treatment [p=] treatment [p=] treatment [p=] treatment




369 0.173 0.318 1 0.380 0.015
395 0.154 0.481 0.670 0.283 0.054
399 0.007 0.012 0.455 0.075 0.019
520 0.051 0.134 1 0.142 0.086
524 0.185 0.156 0.024 0.731 0.061
554 0.816 0.052 0.046 0.077 0.024
* only the p-values of mutations that are either statistical associated or showing the tendency to be associated with antiretroviral
treatment are shown 
*2 all replacements that occurred at the indicated sites were included in the statistic analysis
Table 4. association of selected C-terminal mutations with n-terminal resistance-associated mutations (*)
Position association of C-terminal association of C-terminal association of C-terminal mutations
according to ) mutations with taMs  mutations with naMs with nnRtI-resistance-delivering 
HXB2 (*2 [p=] [p=] mutations [p=]
358 0.095 0.608 0.113
369 0.014 0.008 0.579
395 0.002 0.043 0.112
399 <0.001 0.003 0.205
431 0.139 0.675 0.024
451 0.031 0.409 0.056
468 0.088 0.192 0.585
469 0.103 1 0.014
470 0.761 0.500 0.094
483 1 0.562 0.086
491 0.416 0.561 0.013
509 0.033 0.657 0.062
520 0.097 0.002 0.482
524 0.719 0.044 1
*only the p-values of mutations that are either statistical associated or showing the tendency to be associated to n-terminal re-
sistance-associated mutations are shown
*2 all replacements that occurred at the indicated sites were included in the statistic analysis
1) Stürmer_Umbruchvorlage  15.10.10  18:55  Seite 418substitutions at one position (399) were highly as-
sociated with taMs. these substitutions were also as-
sociated with naMs.
substitutions at two other positions (369 and 395)
were also associated with taMs and naMs. substitu-
tions at two positions (520 and 524) were only associat-
ed with naMs, although substitutions at position 520
showed the tendency to be associated with taMs.  sub-
stitutions at two positions (451 and 509) were associat-
ed with taMs and showed the tendency to be associat-
ed with nnRtI-resistance associated mutations.
furthermore, substitutions at some positions were
only associated with nnRtI-resistance delivering mu-
tations (431, 469 and 491) and there was a trend for
substitutions  at  two  positions  to  be  associated  with
nnRtI-resistance associated mutations (470 and 483).
dIsCussIon
we identified several substitutions in the connection
domain (e.g. n348I, a360V, V365I and t376s), which
have earlier been accounted for an increased aZt-re-
sistance and have been identified in-vivo [6, 12, 16,
17]. the identified substitutions were neither associat-
ed with an antiviral therapy nor with resistance-associ-
ated n-terminal mutations.
Previous studies have shown that especially n348I
is prevalent amongst pre-treated patients and causes
nRtI- and nnRtI-resistance in-vitro and in-vivo [6,
9, 10, 12, 17, 18]. It is able to restore the reduced Rt
activity  of  virus  isolates  containing  the  nRtI-resis-
tance delivering mutation M184V [19]. a recent study
has  shown  that  n348I  may  enable  the  selection  of
both  taMs  and  mutations  that  are  antagonistic  to-
ward taMs [20]. n348I evolves prior to taMs [10,
20].  this  could  explain  the  lacking  association  with
taMs observed in this study. furthermore, it has been
shown  that  the  M184V  mutation  combined  with
taMs is crucial for the development of the n348I
mutation because the n384I mutation restores fitness
loss due to the M184V in a taM background [19]. as
mentioned above only 16 of the analyzed sequences
contained M184V. 
we identified another connection domain substitu-
tion  (E399d)  that  is  associated  with  a  current  anti-
retroviral  treatment  and  nRtI-resistance  delivering
mutations. E399d has previously been reported to be
associated  with  a  significant  reduction  in  etravirine
susceptibility [21]. 
we did not find any of the primer grip substitutions
created by nikolenko et al., which have been shown to
increase aZt-resistance [7]. 
Instead, there were other substitutions, but almost
all of them - except for K476Q - were located in the
connection domain. this finding is consistent with a
recently performed in-vivo study, in which especially
the primer grip residues located in the Rnase H were
conserved  [12].  However,  substitutions  at  these
residues  have  been  found  in-vivo  and  in  database
analyses [3, 11]. such mutations lead to an inefficient
ppt-primer  removal,  which  could  be  fatal  for  viral
replication [22]. another study supports this delibera-
tion,  showing  that  substitutions  at  position  475  and
501 lead to defective viruses [23]. 
only substitutions at one primer grip position (395)
were  associated  with  n-terminal  mutations.  these
substitutions also showed the tendency to be associat-
ed with an aZt-treatment six month prior to sample
taking. K395a was one of the mutations created by
nikolenko et al. that decreased viral replicative capaci-
ty only marginally [7]. this might explain why the oth-
er primer grip substitutions were not associated with
treatment. those substitutions could be silent muta-
tions with no effect on viral resistance or fitness.
Brehm et al. have performed in vitro aZt-selection
experiments in which C-terminal mutations appeared
(R358K,  a371V,  f416y  and  Q509l).  Especially  the
combination of a371V, Q509l and taMs was able to
augment aZt-resistance [8]. 
similar to other in vivo studies we identified substi-
tutions at position 358, 371 and 509 [11, 12, 17]. none
of  these  substitutions  was  associated  with  an  anti-
retroviral treatment, but substitutions at position 358
showed  the  trend  to  be  associated  with  taMs  and
substitutions  at  position  509  were  associated  with
taMs.
two Rnase H mutants (H539n und d549n) creat-
ed  by  nikolenko  et  al.  strongly  increase  aZt-resis-
tance [3]. Both positions were completely conserved in
the analyzed sequences. this is concordant with other
in-vivo studies, although mutations at these positions
have been found in databases [11, 12, 17]. such muta-
tions severely reduce viral replication [24-26]. In addi-
tion, d549n only increased aZt-resistance in combi-
nation with taMs. Even without taMs, H539n in-
creased aZt-resistance strongly, but simultaneously it
decreased the replication capacity more severely, mak-
ing its in-vivo appearance much less likely [3]. 
different  in-vivo  studies  have  described  substitu-
tions at Rnase H residues (469, 470, 554 and 558) [11,
12, 17]. although we also identified such substitutions,
none of them was associated with treatment except
for a554t and the only substitutions associated with
n-terminal resistance delivering mutations were sub-
stitutions at position 469, although substitutions at po-
sition 470 also showed the trend to be associated with
nnRtI  resistance-delivering  mutations.  Resistance
testing has shown that l469I does not increase drug-
resistance  [17].  Positive  effects  on  viral  replication
might explain its association with taMs. 
In the present study, viral sequences isolated from
HIV-1 infected patients treated at the university Hos-
pital frankfurt/Main have been analyzed to evaluate
the  in-vivo  presence  of  C-terminal  substitutions,
which could cause drug-resistance. several previously
reported  substitutions  were  present;  however,  more
studies to evaluate their phenotypic effects are neces-
sary. 
the  statistical  association  of  some  substitutions
with n-terminal resistance-delivering mutations other
than  taMs  is  probably  because  antiretroviral  treat-
ment selects both of them.
other substitutions were associated with n-termi-
nal-resistance-associated  mutations,  although  there
was no correlation to an antiretroviral therapy. an ex-
planation could be that some sequences were derived
from patients, who have been primarily infected by a
virus  from  a  pre-treated  individual.  furthermore,
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ruption at the time of the sampling. a missing selec-
tive pressure could lead to an overgrowth of a virus
with C-terminal mutations by the drug-sensitive wild-
type.  additionally,  genotyping  can  only  show  muta-
tions with a proportion within the quasispecies higher
than 20 percent [27].
a recent study has shown that the combination of
two C-terminal mutations (t369I and n348I) reduces
susceptibility to nRtIs and nnRtIs [28]. there are
only a few other studies, which have considered the
phenotypic  effects  of  combinations  of  C-terminal
mutations. there might be other combinations of C-
terminal mutations leading to an increased drug resis-
tance.
In conclusion, our results show that some of the C-
terminal  mutations  described  in  vitro  are  present  in
patient  isolates.  a  few  of  them  could  be  associated
with antiviral treatment and drug resistance-associated
mutations in the polymerase region. 
due to the low prevalence of C-terminal mutations
and because only a few of them could be associated
with antiviral treatment and drug resistance-associated
mutations in the polymerase region in our study, we
would not recommend routinely testing of the C-ter-
minal Rt region. If new sequencing techniques like
pyrosequencing  become  more  cost  effective,  adding
the C-terminal Rt region to routine testing should be
reconsidered.
However, due to the low prevalence of these C-ter-
minal substitutions in vivo, larger studies will have to
confirm the clinical significance of our findings.
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